Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 11, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to a share buyback.
- Shares Repurchased: 3,000,000 ordinary shares.
- Price per Share: 1,202.6924 pence.
- Treasury Shares Held: 474,194,158 shares (representing 9.01% of total voting rights).
- Shares in Issue: 5,264,371,533 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 3,000,000 repurchased shares. Consequently, the number of shares held in Treasury has increased to 474,194,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding the share repurchase.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (3,000,000 shares at 1,202.6924 pence) against the company's cash position in other financial reports.
- Confirm the updated share count of 5,264,371,533 in issue for accurate earnings per share (EPS) calculations.
- Note that Treasury shares now represent 9.01% of total voting rights, which may impact voting dynamics.
- Ensure the repurchase was executed within the limits authorized at the May 21, 2008 Annual General Meeting.